NCT07134218View on ClinicalTrials.gov

Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Rectal Cancer
Interventions
DRUG

serplulimab、bevacizumab

short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 2 cycles of FOLFOX + serplulimab + bevacizumab → 2 cycles of FOLFOX + serplulimab.

OTHER

neoadjuvant chemoradiation therapy

short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 4 cycles of FOLFOX alone.

Trial Locations (1)

200433

Department of Colorectal Surgery in Changhai Hospital, Shanghai

All Listed Sponsors
lead

Changhai Hospital

OTHER